Close Menu

NEW YORK (GenomeWeb) — Bristol-Myers Squibb and H3 Biomedicine said today that they have partnered to investigate the therapeutic potential of H3's RNA splicing technology.

H3 — a Cambridge, Massachusetts-based subsidiary of Japanese drugmaker Eisai — is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.